Abstract
Despite considerable progress, the treatment of acute leukemia continues to be a challenge for a significant majority of patients. Using a well-characterized preclinical mouse model of acute promyelocytic leukemia (APL), we evaluated here the antileukemic efficacy of RT53, an anticancer peptide with potential immunological properties. Our results indicate that RT53 possesses a direct antileukemic effect, even at a late stage. We also demonstrate that a single injection of a vaccine consisting of leukemic blasts exposed to RT53, which induces the hallmarks of immunogenic cell death, was highly effective in preventing leukemia development in both prophylactic and therapeutic settings. The vaccine comprising RT53-treated APL cells generated long-term antileukemic protection and depletion experiments indicated that CD4 + T cells were of crucial importance for vaccine efficacy. Combined, our results provide the rationale for the exploration of RT53-based therapies for the treatment of acute leukemia.
References
Mar 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·D BrownJ M Bishop
Apr 6, 1999·The Journal of Experimental Medicine·V Lallemand-BreitenbachH de Thé
Dec 12, 2001·Blood·M MohtyB Gaugler
May 10, 2005·Bioorganic & Medicinal Chemistry Letters·Kosuke DodoMikiko Sodeoka
Dec 21, 2005·The Journal of Experimental Medicine·Noelia CasaresGuido Kroemer
Apr 24, 2009·The EMBO Journal·Patricia RigouJean-Luc Poyet
May 7, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miroslaw J SzczepanskiMichael Boyiadzis
Sep 3, 2009·Blood·Qing ZhouBruce R Blazar
Dec 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lee M Ellis, Daniel J Hicklin
Feb 17, 2010·The Journal of Experimental Medicine·Sergio A QuezadaJames P Allison
Jun 10, 2010·Clinical and Experimental Immunology·A J Barrett, K Le Blanc
Nov 26, 2010·International Journal of Cancer. Journal International Du Cancer·Zhang ShenghuiXu Xi
Sep 2, 2011·Blood·Celalettin UstunBruce R Blazar
Apr 5, 2012·Clinical & Developmental Immunology·Rishi Vishal LuckheeramBing Xia
Aug 22, 2012·Molecular and Cellular Probes·Katerina PokornaMarika Pla
Sep 11, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Junliang FuFu-Sheng Wang
Sep 26, 2013·PloS One·Rajesh K SharmaHaval Shirwan
Sep 23, 2014·Blood·John D GibbinsIan F Hermans
Jan 17, 2015·Nature·Manolis Pasparakis, Peter Vandenabeele
May 6, 2015·Oncoimmunology·Oliver KeppLorenzo Galluzzi
Sep 16, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S D MartinB H Nelson
Jul 2, 2016·Blood Cancer Journal·I De Kouchkovsky, M Abdul-Hay
Jul 14, 2016·Cancer Research·Léonard Jagot-LacoussiereJean-Luc Poyet
Nov 4, 2017·Wiener klinische Wochenschrift·Christiane ThallingerChristoph Zielinski
Aug 7, 2018·PloS One·Ewa Pasquereau-KotulaJean-Luc Poyet